Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program
Christopher J. Child(Eli Lilly (United Kingdom)), Werner Blum(University of Kassel), Cheri Deal(Unknown), Nan Jia(Eli Lilly (United States)), Mohamad Maghnie(Istituto Giannina Gaslini), Diego Yeste(Universitat Autònoma de Barcelona), Tohru Yorifuji(Osaka City General Hospital), George P. Chrousos(National and Kapodistrian University of Athens), Annette Richter-Unruh, Agnès Linglart(Assistance Publique – Hôpitaux de Paris), Tomonobu Hasegawa(Keio University), Sandro Loche(Bambino Gesù Children's Hospital), Elizabeth Cummings(Dalhousie University), Michel Polak(Hôpital Necker-Enfants Malades), Sarah Lawrence(Children's Hospital of Eastern Ontario), Ron G. Rosenfeld(Oregon Health & Science University), Alan G. Zimmermann(Eli Lilly (United States)), Barbara Predieri(University of Modena and Reggio Emilia)
Cited by 77
Related Papers
Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I
|The Journal of Experimental Medicine|2010|721
Human leptin levels are pulsatile and inversely related to pituitary–ardenal function
|Nature Medicine|1997|628
Child Health, Developmental Plasticity, and Epigenetic Programming
|Endocrine Reviews|2010|625
Adiponectin and Breast Cancer Risk
|The Journal of Clinical Endocrinology & Metabolism|2004|535